{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T01:14:23Z","timestamp":1778116463650,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clinthera.2014.12.018","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T23:04:25Z","timestamp":1422399865000},"page":"793-803","source":"Crossref","is-referenced-by-count":25,"title":["Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01276288","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tim","family":"Heise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreeraj","family":"Macha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.12.018_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.12.018_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.12.018_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"2","author":"Seman","year":"2013","journal-title":"Clinical Pharm in Drug Dev"},{"key":"10.1016\/j.clinthera.2014.12.018_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2014.12.018_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.12.018_bib6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.12.018_bib7","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.12.018_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2014.12.018_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1559-4564.2006.05513.x","article-title":"Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors","volume":"1","author":"Kabakov","year":"2006","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.clinthera.2014.12.018_bib10","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among united states adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2014.12.018_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinte.167.2.141","article-title":"Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States","volume":"167","author":"Wang","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2014.12.018_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14740330903499240","article-title":"Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds","volume":"9","author":"Sarafidis","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2014.12.018_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of torasemide","volume":"34","author":"Knauf","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2014.12.018_bib14","first-page":"164","article-title":"Pharmacokinetics and metabolism of torasemide in man","volume":"38","author":"Neugebauer","year":"1988","journal-title":"Arzneimittelforschung"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814008790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814008790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T20:25:28Z","timestamp":1537907128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814008790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0149291814008790"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.12.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}